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Letters to the Editor
Fibroblast growth in the soft agar clonogenic assay for
cervix cancer radiosensitivity
Sir,
Recently, West and colleagues published a paper in this journal
summing up their work on radiosensitivity testing in 128 cervix
cancer patients, with a follow-up time from 2 to 5 years (West et
al, 1997). The purpose ofthat study was to test the hypothesis that
tumour cell in vitro radiosensitivity measured before treatment
predicts clinical outcome of the individual patients after curative
radiotherapy alone (Davidson et al, 1990). Tumour biopsies were
obtained before treatment, and cellular in vitro radiosensitivity
was assessed, using the modified Courtenay-Mills soft agar clono-
genic assay, by measuring the fraction of cells surviving after a
radiation dose of 2 Gy (SF2). The study concluded that SF2 was a
significant prognostic parameter for overall survival, local control
and metastasis-free survival, and that this was independent of
disease stage, tumour grade, patient age, colony-forming effi-
ciency and tumour diameter. The biological explanation for this
finding is still not clear-cut, as we now demonstrate, that when
culturing biopsies from carcinoma of the uterine cervix, both
stromal fibroblasts as well as tumour cells can be grown.
Our approach for culturing biopsies from carcinoma of the
uterine cervix involves removing the soft agar, and all the colonies
are collected on preparation slides for identification of the origin
ofthose colonies. For immunocytochemistry, the monoclonal anti-
bodies anti-cytokeratin (AE1-3, Biogenex), reacting with epithe-
lial cells, and anti-vimentin (3B4, Dako), reacting with fibroblasts,
are used (Stausb0l-Gr0n et al, 1995; 1998). Twelve carcinomas of
the uterine cervix (nine squamous cell carcinomas, two adenocar-
cinomas, one adenosquamous carcinoma) met the criteria for
successful growth, with more than ten colonies in the unirradiated
tubes. Plating efficiency, irrespective of cell type ranged from
0.004% to 0.297% with a median of 0.021%, concordant with the
results reported by West et al (1997). The minority ofthe colonies
in the unirradiated cultures of most cervix carcinoma biopsies was
tumour marker positive, ranging from 0% to 93%, with a median
of 26% (Figure 1). In parallel, the unirradiated tubes contained
6-100% fibroblast marker-positive colonies, with a median of
80%. The sum ranged from 80% to 125%. Cellular in vitro
radiosensitivities of tumour cells (tumour cell SF2), fibroblasts
(fibroblast SF2) and an overall estimate (overall SF,) were deter-
mined. In ten patients, overall SF2 ranged from 0.31 to 0.81, with a
median of 0.57. Tumour cell SF2 and fibroblast SF, had median
values of 0.53 (range 0.26-0.67) and 0.55 (range 0.28-1.00)
respectively.
Previous studies on other tumour types support the finding that
primary tumour biopsies are a source of fibroblast colonies when
grown in the modified Courtenay-Mills soft agar clonogenic assay
(Lawton et al, 1994; Stausb0l-Gr0n et al, 1995). In head and neck
carcinomas, the majority ofthe colonies obtained in theunirradiated
tubes originated from fibroblasts, and the overall SF2 was statisti-
cally significantly correlated to an independent measure of fibrob-
last SF, (Stausb0l-Gr0n et al, 1995). Thus, taken together, it may be
likely that the radiosensitivity ofstromal fibroblasts, dominating the
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Figure 1 (A) The percentage of tumour cell colonies out of the total number
of colonies in the unirradiated tubes. (B) The percentage of fibroblast
colonies out of all colonies in the unirradiated tubes. One patient biopsy was
omitted from the figure because the patient material was insufficient for both
immunostainings
pretreatment measure ofoverall SF, predicts clinical outcome after
curative radiotherapy in cervix cancer. However, this suggestion
needs to be tested in another setting, as to our knowledge, no other
study has yet found a significant correlation between the cellular in
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vitro radiosensitivity of tumour specimens (Brock et al, 1990;
Eschwege et al, 1997) or derived cell lines (Allanunis-Turner et al,
1992; Ramsay et al, 1992; Taghian et al, 1993), measured by the
overall SF, and the clinical outcome of individual patients after
curative radiotherapy in any tumour type.
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Reply to the letter from B Stausb0olGr0n et al
Sir,
The above letter reports the predominant growth of fibroblasts
rather than tumour cells in soft agar cultures ofcervix carcinomas.
It then suggests that results generated by my co-workers and I
(West et al, 1997) show that 'it may be likely that' fibroblast
radiosensitivity predicts clinical outcome after radiotherapy in
cervix cancer (Stausb0l-Gr0n et al, 1998). There are four reasons
why I believe they cannot translate their experience to our results.
First, there is the issue of antibody cross-specificity. This
problem is most clearly demonstrated from a study on human lung
tumours cultured in soft agar (Lawton et al, 1995). In the worst case,
three of four colonies examined showed positive staining with
cytokeratin markers and eight of eight colonies showed positive
staining with a fibroblast marker (5B5). That is, for the same
tumour, 75% of the colonies grown were tumour marker positive
and 100% were fibroblast marker positive. The 5B5 monoclonal
antibody stains prolyl 4-hydroxylase, which is involved in collagen
synthesis and has been reported to be specific for fibroblasts
(Esterre et al, 1992). However, both human endothelial
(Schwachula et al. 1994) and macrophage (Labat et al, 1991) cells
have been shown to express 5B5. Although, to my knowledge, it
has not been studied in tumours, it is possible that some will express
5B5. The cervix tumour work of Stausb0l-Gr0n and co-workers
(1998) used the anti-vimentin monoclonal antibody 3B4 as a
marker for fibroblast cells. Unfortunately, vimentin expression is
not fibroblast specific. Vimentin expression in tumour cells may be
a feature of dedifferentiation, and it has been reported for a variety
of tumour types: breast tumours (Gould et al, 1990), sarcomas
(Gerharz et al, 1990), carcinomas of the vulva (Weikel et al, 1996),
lung carcinomas (Blobel et al, 1984) and endometrial carcinomas
(Mobus et al, 1993). In addition, in a series offourcervix carcinoma
lines, two squamous cell carcinomas were shown to be positive for
vimentin expression (Kelland et al, 1987). To complicate the situa-
tion further, tumours can not only express vimentin but they can
also lose keratin expression during cell division (Lane et al, 1982)
and culture (Mackay et al, 1990). In support ofthis, rapidly prolifer-
ating tumours have been shown to have a lower proportion ofcytok-
eratin-positive tumour cells (Wingren et al, 1995).
In our own work, we have looked at low-molecular-weight
cytokeratin expression in some cervix tumours (Davidson et al,
1992). Nine tumours were examined using CAM5.2 (recognizing
cytokeratins 8, 18 and 19) and CKI (recognizing cytokeratins 6
and 18) antibodies, and positive staining of colonies was seen.
Although the majority was positive using both stains, two tumours
were CAM5.2 positive and CK1 negative, showing the importance
of using multiple cytokeratin markers.
Secondly, there is a difference in the method used by the Aarhus
and Manchester groups. In culturing human tumours, we use an
enzyme cocktail followed by a half-hour disaggregation in trypsin
(omitted by the Aarhus group), which is used at a fivefold higher
concentration than used for the routine subculture of monolayer
cells. Trypsin is known to be toxic to fibroblasts and must be used
at a low concentration for a short period of time. Indeed, selective
trypsinization is used in establishing epithelial cultures to prevent
overgrowth by fibroblasts (e.g. Schumann et al, 1988). In addition,
we have quantified the cell types present in cell suspensions
prepared using enzymes from cervix tumours (Davidson et al,
1992). The predominant cell type present is tumour (mean 45%)
followed by granulocyte (mean 24%), lymphocyte (mean 16%)
and macrophage (mean 15%). Fibroblast-like cells are seen rarely.
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